KAIROS PHARMA, LTD. Proceeds from Notes Payable
KAIROS PHARMA, LTD. (KAPA) reported Proceeds from Notes Payable of $142.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-03-31
- KAIROS PHARMA, LTD. proceeds from notes payable for the quarter ending 2024-12-31 was $0.00.
- KAIROS PHARMA, LTD. proceeds from notes payable for the quarter ending 2024-09-30 was $40.00K.
- KAIROS PHARMA, LTD. proceeds from notes payable for fiscal 2024 was $142.00K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $40.00K derived: sum of 2 quarters · filed 2026-03-31 | $142.00K 10-K · filed 2026-03-31 | |
| 2024-09-30 | $40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $142.00K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $102.00K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |